These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19118720)

  • 1. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.
    Belluzzi F; Sernesi L; Preti P; Salinaro F; Fonte ML; Perlini S
    J Am Coll Cardiol; 2009 Jan; 53(1):24-9. PubMed ID: 19118720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].
    Belluzzi F; Sernesi L; Centola M; Perlini S
    Recenti Prog Med; 2009 Nov; 100(11):508-11. PubMed ID: 20066882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
    Salehian O; Healey J; Stambler B; Alnemer K; Almerri K; Grover J; Bata I; Mann J; Matthew J; Pogue J; Yusuf S; Dagenais G; Lonn E;
    Am Heart J; 2007 Sep; 154(3):448-53. PubMed ID: 17719288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
    Fogari R; Derosa G; Ferrari I; Corradi L; Zoppi A; Lazzari P; Santoro T; Preti P; Mugellini A
    Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
    Fazio G; Pizzuto C; Sutera L; Guttilla D; Di Gesaro G; Cascio C; Novo G; Assennato P; Novo S
    Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.
    Lüders S; Schrader J; Berger J; Unger T; Zidek W; Böhm M; Middeke M; Motz W; Lübcke C; Gansz A; Brokamp L; Schmieder RE; Trenkwalder P; Haller H; Dominiak P;
    J Hypertens; 2008 Jul; 26(7):1487-96. PubMed ID: 18551027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
    Williams SG; Connelly DT; Jackson M; Bennett A; Albouaini K; Todd DM
    Europace; 2005 Nov; 7(6):554-9. PubMed ID: 16216757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation.
    Lip GY; Frison L; Grind M
    J Intern Med; 2007 Jun; 261(6):577-86. PubMed ID: 17547713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
    L'Allier PL; Ducharme A; Keller PF; Yu H; Guertin MC; Tardif JC
    J Am Coll Cardiol; 2004 Jul; 44(1):159-64. PubMed ID: 15234426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.
    Spinar J; Vítovec J; Soucek M; Dusek L; Pavlík T;
    Vnitr Lek; 2009 May; 55(5):481-8. PubMed ID: 19514614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term efficacy of combination therapy using antiarrhythmic agents and angiotensin converting enzyme inhibitor in patients with paroxysmal and persistent atrial fibrillation: importance of the timing of administration].
    Komatsu T; Nakamura S; Suzuki O; Horiuchi D; Owada S; Kameda K; Tomita H; Oikawa K; Abe N; Okumura K
    J Cardiol; 2003 Feb; 41(2):73-80. PubMed ID: 12649925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation.
    Boldt A; Scholl A; Garbade J; Resetar ME; Mohr FW; Gummert JF; Dhein S
    Basic Res Cardiol; 2006 May; 101(3):261-7. PubMed ID: 16382287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of ramipril on sympathetic nervous system function in older patients with hypertension.
    Lee CC; Sidani MA; Hogikyan RV; Supiano MA
    Clin Pharmacol Ther; 1999 Apr; 65(4):420-7. PubMed ID: 10223780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reviewing the future of renin-angiotensin system blockade: the role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation.
    Ducharme A; Schiffrin EL
    Can J Cardiol; 2010 Dec; 26 Suppl E():21E-23E. PubMed ID: 21620287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Unsatisfactory results of upstream therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for the prevention of recurrent atrial fibrillation].
    Disertori M; Zeni P; Quintarelli S; Bonmassari R
    G Ital Cardiol (Rome); 2010 Nov; 11(11):829-34. PubMed ID: 21348320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin II receptor blockers in the prevention of atrial fibrillation.
    Barra S; Silvestri N; Vitagliano G; Madrid A; Gaeta G
    Expert Opin Pharmacother; 2009 Jun; 10(9):1395-411. PubMed ID: 19466911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.